(Q42991359)

12 November 2017

0 references

Hepatitis C drug development at a crossroads (English)

1 reference

12 November 2017

David R Nelson

1

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

12 November 2017

1 reference

12 November 2017

volume

50

1 reference

12 November 2017

issue

4

1 reference

12 November 2017

page(s)

997-999

1 reference

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

12 November 2017

cites work

1 reference

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

21 January 2018

1 reference

Predictors of response of US veterans to treatment for the hepatitis C virus

21 January 2018

1 reference

3-drug synergistic interactions of small molecular inhibitors of hepatitis C virus replication

21 January 2018

1 reference

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

21 January 2018

1 reference

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

21 January 2018

1 reference

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

21 January 2018

1 reference

Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/HEP.23208

1 reference

12 November 2017

1 reference